Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy

Extramammary Paget disease (EMPD) is a locally aggressive cutaneous malignancy that usually arises in anogenital or axillary skin. Immune checkpoint inhibitors targeting programmed cell death receptor (PD-1) and/or its ligand (PD-L1) are approved for the treatment of several types of cancer, and res...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2019-05, Vol.11 (6), p.754
Hauptverfasser:	Mauzo, Shakuntala H, Tetzlaff, Michael T, Milton, Denái R, Siroy, Alan E, Nagarajan, Priyadharsini, Torres-Cabala, Carlos A, Ivan, Doina, Curry, Jonathan L, Hudgens, Courtney W, Wargo, Jennifer A, Sahin, Aysegul A, Pettaway, Curtis A, Prieto, Victor G, Aung, Phyu P
Format:	Artikel
Sprache:	eng
Schlagworte:	Anogenital Apoptosis Biopsy Cancer therapies CD3 antigen CD8 antigen Cell death Chemotherapy Cytotoxicity ErbB-2 protein FDA approval Image processing Immune checkpoint inhibitors Ligands Lung cancer Lymphatic system Lymphocytes Malignancy Metastasis Patients PD-1 protein PD-L1 protein Skin Skin cancer Therapeutic targets Tumor cells Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!